Targin

Targin Bioscience is a biotechnology company dedicated to discovering and developing next-generation small molecule inhibitors for high-value oncology targets. The company leverages a proprietary platform designed to target challenging protein-protein interactions (PPIs), with a specific emphasis on the RAS signaling pathway. Targin's lead research programs focus on developing potent, selective inhibitors for KRAS mutations, including KRAS G12D, to treat various solid tumors such as lung, colorectal, and pancreatic cancers. Based in South San Francisco, the company aims to overcome the limitations of current therapies and provide new options for patients with genetically driven cancers. The firm is backed by prominent life science venture capital firms and is currently in the pre-clinical stage of development.